Pharmaceutical compounds
US12384764B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2020 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Oct 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or —NHR8; either (i), a, c and c are all bonds, with, b, d and f absent; or b, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.